PFE vs QCOM: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-16.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
VS
QUALCOMM Incorporated · Technology
$134.47
+77.7% upside to fair value
Med Conviction Grade B
QuantHub Verdict
QCOM has more upside to fair value (+77.7%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE QCOM
Current Price $26.91 $134.47
Fair Value Estimate $35.00 $239.00
Upside to Fair Value +30.1% +77.7%
Market Cap $153.0B $143.6B
Forward P/E 9.5x 26.8x
EV / EBITDA 13.8x
Price / Sales 2.4x 3.2x
Price / FCF 16.8x 11.1x
Revenue Growth YoY -1.6% +8.7%
Gross Margin 70.3% 55.1%
Operating Margin 24.7% 27.1%
Return on Equity 9.0% 21.6%
Dividend Yield 6.4%
FCF Yield 5.9% 9.0%
Analyst Consensus Hold Hold
Investment Thesis
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
QCOM — QUALCOMM Incorporated
Qualcomm Incorporated is a leading semiconductor company specializing in wireless chipsets and IP licensing, with dominant positions in 5G modems via QCT (87% of revenue) and steady QTL royalties. The business excels through a vast patent moat, diversification into automotive and IoT, and robust growth (revenue +13% YoY to $44B in FY2025), but faces risks from Apple modem shifts and China exposur…
Accumulation Zones
Metric PFE QCOM
Zone Low $25.00 $179.00
Zone High $29.00 $203.00
In Buy Zone? Yes Yes
← PFE Research    QCOM Research →    All Research